




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Certificate of Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service as 1.8(a) (Cert.) Mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-11450.


Marvin Feldman

Dated: February 15, 2005

Applicant hereby petitions that any and all extensions of the term necessary to render this response timely be granted. Costs for such extension(s) and or any other fee due with this paper, not fully covered by an enclosed check may be charged to Deposit Account #10-0100.

Inventors: Kenneth Curry

Serial No: 10/019,890

Filed: 6/5/2002

Examiner: Paul A. Zucker

Art Unit: 1621

Title: 2-AMINOINDANE ANALOGS

Docket No: MBMCO.P-1

Customer Code: 28752

MS: Box Fee
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Sir:

It is respectfully requested that the art listed on the attached PTO Form-1449 be considered by the Patent Examiner in the above-identified application and made of record therein by including same in the "references cited" portion of any patent

issuing from this application. The documents noted therein are issued patents and/or publications, and thus are being brought to the Examiner's attention. Full text copies are enclosed or will follow as soon as possible once they are made available to the undersigned, and this submission is otherwise believed to be in compliance with 37 CFR 1.56 and 1.97 - 1.98.

No representation is made or intended, that better art than that listed is not available, nor is a representation made or intended that any translations supplied are accurate or complete. Also, no representation is made or intended that the order of information listed is significant, or that a search has been made by the applicant.

None of the patents/publications, whether taken alone or together, are believed to disclose or suggest the subject invention as claimed. It is, therefore, believed that the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by such patents and/or publications. However, as indicated initially in this statement, it is respectfully requested that the Examiner consider such information under 37 CFR 1.104.


The required fee for submission of this Supplemental Information Disclosure Statement and PTO Form 1449 in the amount of \$180 is enclosed. Should there be additional fees required or a credit is forthcoming, then same may be charged or credited to the

undersigned Attorneys Deposit Account 10-0100.

Respectfully submitted,

LACKENBACH SIEGEL LLP

By:


MARVIN FELDMAN

Reg. No. 25,797

MF:k

Dated: Mar 15, 2005
One Chase Road
Scarsdale, N.Y. 10583
(914) 723-4300

Enclosures: \$180 Check
References

ATTY. DOCKET NO.
 MBMCO.P1

SERIAL NO.
 10/019,890

SUPPLEMENTAL INFORMATION
 DISCLOSURE CITATION



(Use several sheets if necessary)

APPLICANT: Kenneth
 Curry

FILING DATE: 6/8/2002

GROUP: 1621

U. S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Patent
	3,704,312	U.S. Patent
	3,746,495	U.S. Patent
	4,291,050	U.S. Patent
	4,775,695	U.S. Patent
	5,011,472	U.S. Patent
	5,023,252	U.S. Patent
	5,329,049	U.S. Patent
	5,360,936	U.S. Patent
	5,948,807	U.S. Patent
	5,321,032	U.S. Patent

Foreign Patent Documents

Examiner's Initial	Document Number	Country Patent / document
	No. 77122	EP Patent
	No. 1179060	GB Patent
	No. 1313429	GB Patent
	No. 2041655	DE Patent
	WO 91/12266	International Publication
	WO 92/11858	International Publication
	WO 93/08799	International Publication
	WO 94/15917 A	International Publication
	WO 94/15924	International Publication
	WO 96/15100	International Publication
	WO 96/16081	International Publication
	WO 97/30992	International Publication

Other Documents (including author, title, date, pages, etc.)

Examiner's Initial	PUBLICATIONS Author/Publication/Pages
	Adham, N. et al., Proc. Natl. Acad. Sci., 1993, 90:408-412
	Akiyama et al., Brain Res., 1992, 569:71-77
	Aramori and Nakanishi, Neuron, 1992, 8:757-765
	Bashir et al., Nature, 1993, 363:347-350
	Blair, I. et al., Aust. J. Chem., 1979, 32:1055-65
	Brabet et al., Neuropharmacology, 1995, 34:895-903

	CA:95:61830 abs of Journal of Institution of Chemists (India) by Gautam et al., 53(1):27-29 (1981)
	CA:125:114326 abs of WO9615099 May 1996
<i>OTPE FEB 18 2005 PRINT & TRANSLATE</i>	CA:129:343698 abs of Peptides 1996 symposium Proceedings of European Peptide Symposim by Lehmann et al., 24th Edinburgh Sept 8-13 pp. 573-574 (1996)
	CA:130:177836 abs of Neuropharmacology by Thomsen et al 37(12) pp 1465-73 (1998)
	CA:135:132201 abs of Experimental Neurology by Faden et al 167(2) pp 435-44 (2001)
	CA:135:267255 abs of WO2001072291 October 2001
	CA:136:310133 abs of Chinese Journal of Chemistry by Ding et al. 19(12) pp 1232-8 (2001)
	Cannon, J. et al., J. Med. Chem., 1974, 17(5):565-8
	Chemical Abstracts, Vol. 110, No. 15, April 10, 1989 (Aboul-Enein, M.N. et al., Sci. Pharm., 1988, 56:243-250)
	Chemical Abstracts, Vol. 118, No. 1, January 4, 1993
	Chemical Abstracts, Vol. 119, No. 15, October 11, 1993 (JP5085999)
	Chemical Abstracts, Vol. 122, No. 21, May 22, 1995
	Chemical Abstracts, Vol. 124, No. 5, January 29, 1996 (Yang C., et al., J. Chem. Soc., Perkin Trans. I, 1995, 879-887)
	Chemical Abstracts, Vol. 81, No. 7, August 19, 1974 (Cyberman Craig, J. et al., J. Org. Chem., 1974, 39(12):1669-1676)
	Chiamulera et al., Eur. J. Pharmacol., 1992, 216:335-336
	Deeks, T. et al., J. Med. Chem., 1983, 26(5):762-5
	Deeks, T. et al., J. Pharm. Sci., 1984, 73(4):457-60
	Desai, M.A. and Conn, P. J., Neuroscience Lett., 1990, 109:157-162
	Eaton, S. A. et al., Eur. J. Neuroscience, 1993, 5:186-189
	Gavuzzo, E. et al., Int. J. Pept. Protein Res., 1991, 37(4):268-76
	Grouiller, A. et al., Eur. J. Med. Chem. - Chim. Ther., 1980, 15(2):139-46
	Hayashi et al., J. Neurosci., 1994, 14:3370-3377
	Hayashi et al., Nature, 1993, 366:687-690
	Hayashi, Y. et al., Br. J. Pharmacol., 1992, 107:539-543
	Hsieh, Kun-Hwa et al., J. Med. Chem., 1979, 22(9):1038-44
	Josien H., J. Med. Chem., 1994, 37:1586-1601
	Knopfel et al., J. Med. Chem., 1995, 38:1417-1426
	Koh et al., Proc. Natl. Acad. Sci. USA, 1991, 88:9431-9435
	Leftheris, K. et al., J. Med. Chem., 1996, 39(1):224-36
	Linden et al., Neuron, 1991, 7:81-89
	Ma et al., Journal of Organic Chemistry, 64:120-125, published on the Web 12/11/1996
	Mendel, D. et al., J. Am. Chem. Soc., 1993, 115(10):4359-60
	Moreno-Manas, M. et al., Liebigs Ann., 1995, 10:1807-14
	Mosberg, H. et al., J. Med. Chem., 1994, 37(25):4371-83
	Norris, R. et al., Phytochemistry, 1975, 14:393-6
	Obrecht, D. et al., Helv. Chim. Acta, 1992, 75(5):1666-96
	Palacin, S. et al., J. Am. Chem. Soc., 1997, 119(49):11807-11816
	Palmer, E., Monaghan, D.T. and Cotman, C.W., Eur. J. Pharmacol., 1989, 166:585-587
	Pellicciari et al., J. Med. Chem., 1995, 38:3717-3719
	Prelog, V. and Helmchen, G., Angew. Chem. Int. Ed. Engl., 1982, 21:567-583
	Sacaan and Schoepp, Neuroscience Lett., 1992, 139:77-82
	Sacaan et al., J. Neurochemistry, 1992, 59:245-251
	Sarges, R. et al., J. Med. Chem., 1988, 31(1):230-43
	Schiller, P. et al., J. Med. Chem., 1991, 34(10):3125-32
	Schoepp, D., Trends in Pharmacological Science, 1990, 11:508-515
	Schoepp and Conn, Trends in Pharmacological Science, 1993, 14:13-20

Schoepp, D.D. and Johnson, B.G., J. Neurochemistry, 1989, 53:1865-1913
Schoepp, D.D. et al., J. Neurochemistry., 1991, 56:1789-1796
Tanabe et al., J. Neurosci., 1993, 13:1372-1378
Tanabe et al., Neuron, 1992, 8:169-179
Taylor, J. et al., J. Med. Chem., 1970, 13(6):1226-7
Thomsen, C. et al., Eur. J. Pharmacol., 1992, 227:361-362
Thomsen, C. and Suzdak, P., Eur. J. Pharmacol., 1993, 245:299-301
Thomsen, C. et al., J. Neurochem., 1993, 63:2038-2047
Tovey et al., Clinica Chimica Acta, 1974, 56:221-234
Weinshank, R.L., et al., Proc. Natl. Acad. Sci. (USA), 1992, 89:3630-3630
Wickelgren, I. Science, 1998, 280:2045-2047
Zheng and Gallagher, Neuron, 1992, 9:163-172
Zon, J. et al., Liebigs Ann. Chem., 1992, 6:625-628

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PLEASE ALSO CHARGE ANY FEE DUE FOR THE FILING OF THIS FORM TO DEPOSIT ACCOUNT NO. 10-0100